SCHEMBL186167

SCHEMBL186167

Cc1ncc(C(=O)O)s1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9653796 0.98 HCAR2 (0.96) —
SCHEMBL27858708 0.84 HCAR2 (0.72) —
SCHEMBL13451803 0.83 HCAR2 (0.70) —
SCHEMBL4781387 0.82 — —
SCHEMBL1107386 0.81 HCAR2 (0.68) —
SCHEMBL328096 0.80 — —
SCHEMBL1435803 0.80 — —
Hydrochloric Acid SCHEMBL31078491 0.78 HCAR2 (0.64) —
Hydrochloric Acid SCHEMBL29217424 0.78 HCAR2 (0.64) —
SCHEMBL12277009 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113943263-B Synthesis method of 2- (aminomethyl) -1, 3-thiazole-5-carboxylic acid methyl ester 凯美克(上海)医药科技有限公司 2025-03-21 — — CN claimed
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2025-03-13 — — US claimed
CN-119265552-A Chemical nickel-plating palladium-gold solution 生益电子股份有限公司 2025-01-07 — — CN claimed
CN-110167944-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-08-23 — — CN claimed
EP-3672952-B1 BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 — — EP claimed
EP-3661941-B1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 — — EP claimed
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-09-29 — — US claimed
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2022-09-27 — — US claimed
US-11192899-B2 Quinoxaline derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2021-12-07 — — US claimed
US-11186592-B2 Thiazolopyridine derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2021-11-30 — — US claimed
US-20150225450-A1 BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LTD (GB) 2015-08-13 — — US claimed
US-20150203534-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS FLUORINOV PHARMA INC. (CA) 2015-07-23 — — US claimed
EP-2885314-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS Fluorinov Pharma Inc. (CA) 2015-06-24 — — EP claimed
US-9051249-B2 Benzylamine derivatives as inhibitors of plasma kallikrein KALVISTA PHARMACEUTICALS LIMITED (GB) 2015-06-09 — — US claimed
WO-2014108685-A1 PHARMACEUTICAL COMPOSITIONS KALVISTA PHARMACEUTICALS LIMITED (GB) 2014-07-17 — — WO claimed
EP-2729443-A1 BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN Kalvista Pharmaceuticals Limited (GB) 2014-05-14 — — EP claimed
CN-103687846-A Benzylamine derivatives as inhibitors of plasma kallikrein KALVISTA PHARMACEUTICALS LTD 2014-03-26 — — CN claimed
WO-2014026282-A1 FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS SLASSI ABDELMALIK (CA) 2014-02-20 — — WO claimed
WO-2013005045-A1 BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN KALVISTA PHARMACEUTICALS LIMITED (GB) 2013-01-10 — — WO claimed
CN-101475541-B Preparation of 4-methyl thiazole-5-carboxyl acid HATAI KE YANGZHOU MATERIALS CO LTD 2011-05-25 — — CN claimed
Send feedback